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Background: In 2006, we reported the effectiveness of chemoradiotherapy for postoperative recurrent esophageal
cancer with a median observation period of 18 months. The purpose of the present study was to update the
results of radiotherapy combined with nedaplatin and 5-fluorouracil (5-FU) for postoperative loco-regional recurrent
esophageal cancer.
Methods: Between 2000 and 2004, we performed a phase II study on treatment of postoperative loco-regional
recurrent esophageal cancer with radiotherapy (60 Gy/30 fractions/6 weeks) combined with chemotherapy
consisting of two cycles of nedaplatin (70 mg/m2/2 h) and 5-FU (500 mg/m2/24 h for 5 days).
The primary endpoint was overall survival rate, and the secondary endpoints were progression-free survival rate,
irradiated-field control rate and chronic toxicity.
Results: A total of 30 patients were enrolled in this study. The regimen was completed in 76.7% of the patients.
The median observation period for survivors was 72.0 months. The 5-year overall survival rate was 27.0% with a
median survival period of 21.0 months. The 5-year progression-free survival rate and irradiated-field control rate
were 25.1% and 71.5%, respectively. Grade 3 or higher late toxicity was observed in only one patient. Two
long-term survivors had gastric tube cancer more than 5 years after chemoradiotherapy.
Pretreatment performance status, pattern of recurrence (worse for patients with anastomotic recurrence) and
number of recurrent lesions (worse for patients with multiple recurrent lesions) were statistically significant
prognostic factors for overall survival.
Conclusions: Radiotherapy combined with nedaplatin and 5-FU is a safe and effective salvage treatment for
postoperative loco-regional recurrent esophageal cancer. However, the prognosis of patients with multiple regional
recurrence or anastomotic recurrence is very poor.
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Extended radical esophagectomy with three-field (neck,
mediastinum, and abdomen) lymph node dissection has
been performed since the mid-1980’s, and it seems to
have improved survival of patients with esophageal can-
cer [1-3]. However, there is recurrence in 27-52% of
operated patients and loco-regional recurrence in 41.5-
55% of patients with postoperative recurrence [3-9]. In
2006, we reported the effectiveness of radiotherapy and
concurrent chemotherapy for postoperative recurrent
esophageal cancer with a median observation period of
18.0 months [10]. Although the results were better than
those of other studies using radiotherapy with or with-
out chemotherapy, the observation period was not suffi-
cient. Furthermore, there have been no prospective
studies with a long-term observation period for patients
with postoperative loco-regional recurrent esophageal
cancer.
The purpose of the present study was to update the
results of the phase II study of definitive radiotherapy
with nedaplatin (CDGP) and 5-fluorouracil (5-FU) for
loco-regional recurrent esophageal cancer after curative
resection.
Methods
The present study was performed between 2000 and
2004 in Tohoku University Hospital and two affiliated
hospitals according to the following protocol.
All patients had histologically proven squamous cell
carcinoma of the esophagus. Patient selection criteria
included 1) 30 to 80 years of age, 2) Eastern Cooperative
Oncology Group (ECOG) performance status of 0 to 3,
3) no other active cancer, 4) no serious cardiac, liver, or
pulmonary disease, 5) creatinine clearance of more than
50 ml/min, 6) adequate bone marrow function (leukocyte
count of 4000/μl, platelet count of 100,000/μl, 7) loco-
regional recurrence (including para-aortic lymph node
metastasis) without distant metastasis after no residual
tumor (R0) resection by extended radical esophagectomy
with three-field (neck, mediastinum, and abdomen)Figure 1 Schedule of the protocol of chemoradiotherapy.lymph node dissection, and 8) no previous therapy other
than R0 resection.
Recurrence was diagnosed comprehensively by upper
gastrointestinal endoscopy, ultrasonography, computed
tomography (CT), physical findings and/or cytology.
Radiotherapy
A linear accelerator (4 MV or 10 MV) was used as the
X-ray source. The target volume was localized for radio-
therapy in all patients by CT planning. The daily frac-
tional dose of radiotherapy was 2.0 Gy, administered
5 days a week, and the total dose was 60.0 Gy. For 11
patients, a T-shaped field (including the bilateral supra-
clavicular, mediastinal and abdominal regions) was used.
For the remaining 19 patients, extended local fields with
a margin of 1 to 2 cm from the macroscopic tumor were
used. After 40 Gy, the field was changed in all patients
to avoid the spinal cord, and only macroscopic lesions
were irradiated with a margin of 1 to 1.5 cm.
Chemotherapy
Each cycle of chemotherapy consisted of 120-minute
infusion of CDGP at 70 mg/m2 and a 5-day period of
5-FU at 500 mg/m2/day. This cycle of chemotherapy was
repeated with an interval of 4 weeks, for a total radio-
therapy dose of 60 Gy (Figure 1). When toxicity of grade
3 or higher was noted and prolonged, we suspended
or discontinued chemotherapy or reduced the dose
of CDGP alone or the dose of both CDGP and 5-FU by
25-30% in the subsequent cycle.
Completion of the regimen in this study was defined
as completion of two cycles of full-dose CDGP + 5-FU
for a total radiotherapy dose of 60 Gy without suspen-
sion of treatment.
Endpoint
The primary endpoint of the present study was overall
survival rate, and the secondary endpoints were
progression-free survival rate, irradiated-field control
rate and late toxicity.
































1 70 male IIA 6 1 subclavicular/
mediastinal
T-shaped 2 PR yes yes dead 6.5
2 64 male III 6 1 mediastinal T-shaped 2 SD yes yes dead 14
3 64 male IIA 47 1 anastomosis/
subclavicular/
mediastinal
T-shaped 2 SD no yes dead 5
4 50 male III 12 1 abdominal local 2 PR no yes dead 8
5 64 male III 7 1 mediastinal/
abdominal
local 1 SD no yes dead 5
6 62 male III 13 2 anastomosis T-shaped 2 PR no yes dead 4
7 55 male III 5 3 anastomosis/
subclavicular/
abdominal
local 2 PR no yes dead 5.5
8 61 female IIB 28 0 mediastinal T-shaped 2 C R no no alive 54
9 64 male III 8 0 anastomosis/
mediastinal
T-shaped 2 C R yes yes dead 23.5
10 62 male IIB 22 1 abdominal local 2 PR no yes dead 10
11 65 male I 102 0 mediastinal T-shaped 2 C R no no alive 90
12 60 male IV B 6 1 subclavicular local 2 PR no no alive 98
13 72 male III 7 0 abdominal local 2 PR no yes dead 39
14 67 male III 46 0 subclavicular T-shaped 2 C R no no alive 49.5
15 54 male n.a. 4 0 abdominal local 2 SD no yes dead 12
16 68 male III 19 1 anastomosis/
subclavicular
local 2 PR no yes dead 33
17 69 male III 6 1 anastomosis/
subclavicular
local 2 PR no yes dead 28.5
18 68 male n.a. 36 2 mediastinal local 2 PR no no dead 18.5
19 62 male III 10 1 mediastinal local 2 PR no no alive 16.5
20 66 male IV B 66 0 subclavicular local 1 PR yes yes dead 116
21 57 male III 11 3 anastomosis T-shaped 2 PR no no dead 8
22 52 male III 23 1 mediastinal T-shaped 1 PD no yes dead 6
23 56 male I 54 1 anastomosis local 1 PR no no dead 6
24 62 male IIB 23 0 mediastinal local 2 PR no no alive 125.5

















Table 1 Patients’ characteristics (Continued)
26 61 male I 83 1 abdominal local 2 SD yes yes dead 42
27 72 male III 16 0 mediastinal local 1 SD no no alive 29
28 71 male III 6 2 anastomosis T-shaped 2 C R yes yes dead 13.5
29 63 male III 39 0 mediastinal local 2 PR no yes dead 45
30 72 male III 4 1 mediastinal local 2 PR no yes dead 21
* UICC: Union for International Cancer Control.
† ECOG: Eastern Cooperative Oncology Group.

















Figure 2 Overall survival, progression-free survival and
irradiated-field control rates in patients with postoperative loco-
regional recurrent esophageal cancer (Kaplan-Meier method).
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Follow-up evaluations were performed every 3–6
months for the first 2 years and every 12 months there-
after by endoscopy and CT.
Only progression disease (PD) according to Response
Evaluation Criteria In Solid Tumors (RECIST) was
defined as failure of the present regimen (relapse again).
Toxicity
Toxicity was graded according to the Common Termin-
ology Criteria for Adverse Events (CTCAE v3.0). An ad-
verse effect at more than 90 days after completion of
chemoradiotherapy was defined as late toxicity.
Statistics
Survival estimates were calculated using the Kaplan-
Meier method from the first date of radiotherapy, and
differences were evaluated by the log-rank test. Age
(65 years or less vs. more than 65 years), preoperative
stage (I-II vs. III-IV: Union for International Cancer
Control 1997 (UICC1997)), time interval between sur-
gery and recurrence (12 months or less vs. more than
12 months), pre-radiotherapy performance status (0–1 vs.
2–3), radiation field (local alone vs. T-shaped), acute
tumor response according to RECIST (complete regres-
sion (CR) ~ partial regression (PR) vs. stable disease
(SD) ~ PD), number of cycles of chemotherapy (one vs.
two), pattern of recurrence (anastomotic vs. non-anasto-
motic) and number of recurrent regions (one region vs.
multiple regions) were entered into the log-rank test. A
p value of less than 0.05 was considered significant. All
analyses were performed using SPSS 20.0.
The present study protocol was reviewed and approved
by our institutional review board (No. 2012-1-129), and
informed consent was obtained from each patient before
conducting the treatment.
Results
From 2000 to 2004, a total of 30 patients (29 males, 1 fe-
male; median age, 64 years; age range, 50 to 72 years)
were enrolled in this phase II study. Patient characteris-
tics are shown in Table 1. The rate of completion of this
regimen without reduction of chemotherapy was 76.7%.
The median observation period was 72 months (range,
16.5 to 125.5 months) for patients who survived. At the
last observation date, 18 of the 30 patients had relapse
again. Twenty-two of the 30 patients died: deaths were
due to progression disease in 19 patients, intercurrent
diseases in 2 patients and an iatrogenic cause in one
patient.
The 3-year and 5-year overall survival rates were
38.4% (95% confidence interval (CI) = 20.8-56.5) and
27.0% (95% CI = 10.3-43.7), respectively, with a median
survival period of 21.0 months (95% CI = 2.5-39.5). The3-year and 5-year progression-free survival rates were
29.3% (95% CI = 12.8-45.9) and 25.1% (95% CI = 9.1-
41.2), respectively, and both of the 3-year and 5-year
irradiated-field control rates were 71.5% (95% CI = 51.8-
91.2) (Figure 2).
Acute toxicities have already been reported in our pre-
vious report [10]. As the major late toxicity, only one pa-
tient had grade 3 or higher toxicity. The patient died
6 months after completion of the protocol due to serious
pericardial effusion. There was no other grade 3 or
higher late toxicity, although grade 1 or 2 focal pulmon-
ary fibrous change, pericardial effusion and/or pleural ef-
fusion were often observed. Although not toxicity, there
were 2 patients who developed gastric tube cancer,
which could be controlled with endoscopic submucosal
dissection.
In log-rank test, the difference between overall survival
rate in performance status (p = 0.007), pattern of recur-
rence (p = 0.014) and number of recurrent lesions (p =
0.003) were statistically significant (Table 2).
Discussion
There have been some studies on the effectiveness of
radiotherapy with or without chemotherapy for treat-
ment of postoperative recurrent esophageal cancer. In
those studies, even the 2-year survival rates were only
15-31% with short-term observation (Table 3) [11-15].
We previously reported preliminary results of the
present study, which were excellent. Here, updated
results with long-term observation are reported. Al-
though the results are worse than those in the past pre-
liminary report [10], the results of the current regimen
remain one of the best achievements for patients with
postoperative loco-regional recurrent esophageal cancer.
Table 2 Prognostic factors for overall survival




performance status 0-1 25 33.0 0.007
2-3 5 8.0
age ≥65 12 33.0 0.172
<65 18 10.0
preoperative stage (UICC§ 1997) I-II 9 42.0 0.229
III- IV 21 21.0
number of cycles of chemotherapy 1 5 6.0 0.577
2 25 23.5
time interval between surgery and recurrence ≤12 15 14.0 0.176
>12 15 42.0
tumor response (RECIST*) CR-PR 22 23.5 0.466
SD-PD 8 12.0
field local 19 33.0 0.480
T-shaped 11 13.5
number of recurrent regions one 23 39.0 0.014
multiple 7 6.5
pattern of recurrence anastomotic 9 8.0 0.003
non-anastomotic 21 42.0
§UICC: Union for International Cancer Control, *RECIST: Response Evaluation Criteria in Solid Tumors.
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http://www.biomedcentral.com/1471-2407/12/542Recurrence after surgery can now be detected earlier
due to improvements in the resolution of CT. It might
improve recently the treatment results for postoperative
loco-regional recurrent esophageal cancer. FDG-PET/
CT, which enables detection of recurrence at an earlier
stage than that by only CT, has been used frequently
since the mid-2000’s for esophageal cancer, and the
prognosis of loco-regional recurrent esophageal cancer
may therefore be further improved.
We previously reported excellent results of chemora-
diotherapy for solitary lymph node metastasis after cura-
tive surgery for esophageal cancer [16], and the results
for patients with recurrence in one region were also sig-
nificantly better than those for patients with recurrence
in more than one region in the present study. This
supports our hypothesis that the concept of oligo-Table 3 Contents and results of radiotherapy (with or withou
cancer in past studies
author year No. regimen
JL Raoul12) 1995 24 RT† + CDDP*+5-FU
K Nemoto13) 2001 33 RT alone (21) or RT +
CDDP+ 5-FU (12)
Y Nishimura11) 2003 13 RT + CDDP+5-FU
Y Shioyama14) 2007 82 RT ± chemotherapy
K Maruyama15) 2011 23 RT ± chemotherapy
Current study 2012 30 RT + CDGP§+ 5-FU
†RT: radiotherapy, * CDDP: cisplatin, § CDGP: nedaplatin, # 5-FU: 5-fluorouracil, ‡n.arecurrence [17] might also be applicable to postoperative
esophageal cancer, especially in cases without anasto-
motic recurrence.
The appropriate irradiation field for postoperative
loco-regional recurrent esophageal cancer has not been
clarified. In the present study, there were some patients
in whom recurrent lesions could not be controlled, but
there were no patients who had regional lymph node re-
currence after chemoradiotherapy. In our previous study
on solitary lymph node metastasis [16], there were 2
patients who showed other lymph node metastases after
chemoradiotherapy, but both of those patients had
undergone irradiation with a T-shaped field. Further-
more, patients who were treated with a T-shaped field
had a significantly higher rate of adverse events than did







14 months 17.1% n.a. ‡
n.a. 15% n.a.
9.5 months 19% n.a.
n.a. 22% 11%
n.a. 31% 24%
72 months 46.0% 27.0%
.: not available.
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tube even with 60 Gy; however, there have been some
reports of problems in the gastric tube caused by ob-
struction of blood flow [18,19], which can be induced by
radiation. Therefore, we do not recommend irradiation
with a prophylactic field such as a T-shaped field for
postoperative loco-regional recurrent esophageal cancer.
Furthermore, Zhang et al. reported that results for
patients treated with 60 Gy or more were significantly
better than results for patients treated with less than
60 Gy in patients with postoperative loco-regional recur-
rent esophageal cancer [20], and we reported in 2001
that one of our patients died of necrosis of the gastric
tube 6 months after the end of 66 Gy radiotherapy [13].
According to those reports and the present results, the
appropriate radiation dose for loco-regional recurrent
esophageal cancer might be 60 Gy.
In the present study, 2 of the 5 patients who survived
for more than 5 years after chemoradiotherapy had gas-
tric tube cancer, which fortunately could be completely
resected by endoscopic submucosal resection (ESD). In
the past, when esophageal cancer patients seldom sur-
vived for a long time, the occurrence of gastric tube
cancer was considered to be infrequent [21]. Recent
improvements in the survival of patients after esopha-
gectomy, however, have led to increasing occurrence of
gastric tube cancer [22,23]. Bamba et al. reported that
the 10-year cumulative incidence of gastric tube cancer
after esophagectomy was 8.6% [24], and they described
the possible cause of the high incidence of gastric can-
cer after esophagectomy. Asian people have a high rate
of Helicobacter pylori infection and therefore have a
high risk of gastric cancer [25]. Upper gastrointestinal
endoscopy once or twice per year is recommended for
follow-up after treatment for postoperative loco-
regional recurrent esophageal cancer. Gastric tube
cancer is one of the major complicating diseases in
patients who survive for a long time after treatment of
esophageal cancer.
Conclusions
The present protocol of radiotherapy combined with
CDGP and 5-FU is a safe and effective salvage treatment
for postoperative loco-regional recurrent esophageal
cancer. However, the prognosis of patients with multiple
regional recurrence or anastomotic recurrence is very
poor.
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